Abstract
A simple, efficient and reproducible method to transduce proteins into mammalian cells has not been established. Here we describe a novel protein transduction method based on a lentiviral vector. We have developed a method to package several thousand foreign protein molecules into a lentivirus-like nanoparticle (LENA) and deliver them into mammalian cells. In this proof-of-concept study, we used β-lactamase (BlaM) as a reporter molecule. The amino-terminus of BlaM was fused to the myristoylation signal of lyn, which was placed upstream of the amino-terminus of Gag (BlaM-gag-pol). By co-transfection of plasmids encoding BlaM-gag-pol and vesicular stomatitis virus-G (VSV-G) into 293T cells, LENA were produced containing BlaM enzyme molecules as many as Gag per capsid, which has been reported to be ∼5000 molecules, but lacking the viral genome. Infection of 293T and MT-4 cells by VSV-G-pseudotyped BlaM-containing LENA led to successful transduction of BlaM molecules into the cell cytoplasm, as detected by cleavage of the fluorescent BlaM substrate CCF2-AM. LENA-mediated transient protein transduction does not damage cellular DNA, and the preparation of highly purified protein is not necessary. This technology is potentially useful in various basic and clinical applications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
MacGregor RR . Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum Gene Ther 2001; 12: 2028–2029.
Cockrell AS, Kafri T . Gene delivery by lentivirus vectors. Mol Biotechnol 2007; 36: 184–204.
McCart JA, Bartlett DI . Lentiviral Vectors. In: Templeton NS (ed.). Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 3rd edn. CRC Press: Carrollton, 2008, pp 245–262.
Lundberg C, Björklund T, Carlsson T, Jakobsson J, Hantraye P, Déglon N et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008; 8: 461–473.
Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE . Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988; 331: 280–283.
Klein KC, Reed JC, Lingappa JR . Intracellular destinies: degradation, targeting, assembly, and endocytosis of HIV Gag. AIDS Rev 2007; 9: 150–161.
Briggs JA, Simon MN, Gross I, Kräusslich HG, Fuller SD, Vogt VM et al. The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 2004; 11: 672–675.
Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, Miller MD et al. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 2004; 78: 3429–3435.
Urano E, Aoki T, Futahashi Y, Murakami T, Morikawa Y, Yamamoto N et al. Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production. J Gen Virol 2008; 89: 3144–3149.
Aoki T, Shimizu S, Urano E, Futahashi Y, Hamatake M, Tamamura H et al. Improvement of lentiviral vector-mediated gene transduction by genetic engineering of the structural protein Pr55(Gag). Gene Therapy 2010; 17: 1124–1133.
Voelkel C, Galla M, Maetzig T, Warlich E, Kuehle J, Zychlinski D et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci USA 2010; 107: 7805–7810.
Hubner W, Chen P, Del Portillo A, Liu Y, Gordon RE, Chen BK . Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. J Virol 2007; 81: 12596–12607.
Campbell RE . Realization of beta-lactamase as a versatile fluorogenic reporter. Trends Biotechnol 2004; 22: 208–211.
Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, Foley P et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 2000; 11: 2403–2413.
Ulett GA, Han S, Han JS . Electroacupuncture: mechanisms and clinical application. Biol Psychiatry 1998; 44: 129–138.
Ford KG, Souberbielle BE, Darling D, Farzaneh F . Protein transduction: an alternative to genetic intervention? Gene Therapy 2001; 8: 1–4.
Zhang Y, Yu LC . Microinjection as a tool of mechanical delivery. Curr Opin Biotechnol 2008; 19: 506–510.
Cavrois M, De Noronha C, Greene WC . A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 2002; 20: 1151–1154.
Yamanaka S, Blau HM . Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010; 465: 704–712.
Komano J, Miyauchi K, Matsuda Z, Yamamoto N . Inhibiting the Arp2/3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses. Mol Biol Cell 2004; 15: 5197–5207.
Stauffer TP, Ahn S, Meyer T . Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells. Curr Biol 1998; 8: 343–346.
Miyauchi K, Komano J, Yokomaku Y, Sugiura W, Yamamoto N, Matsuda Z . Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. J Virol 2005; 79: 4720–4729.
Acknowledgements
This work was supported by the Japan Health Science Foundation, the Japanese Ministry of Health, Labor, and Welfare (H18-AIDS-W-003 to JK) and the Japanese Ministry of Education, Culture, Sports, Science and Technology (18689014 and 18659136 to JK).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Aoki, T., Miyauchi, K., Urano, E. et al. Protein transduction by pseudotyped lentivirus-like nanoparticles. Gene Ther 18, 936–941 (2011). https://doi.org/10.1038/gt.2011.38
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2011.38
Keywords
This article is cited by
-
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
Communications Biology (2022)
-
Virus-Like Particles Derived from HIV-1 for Delivery of Nuclear Proteins: Improvement of Production and Activity by Protein Engineering
Molecular Biotechnology (2017)
-
Therapeutic potential of HIV protease-activable CASP3
Scientific Reports (2012)